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Abstract 
Section I: Four analogues of parathyroid hormone (PTH) containing D-amino 
acids were synthesized. Substitutions were made within the fully biologi¬ 
cally active fragment of parathyroid hormone in the amino-terminal region, 
at position 2, and at the carboxyl-terminus, at position 34. The carboxl- 
terminal region contains structural determinants important to receptor 
binding. The amino-terminal region plays a critical role in the hormone- 
stimulated activation of adenylate cyclase in vitro and the expression 
of hormonal activity in vivo. Placement of a D-amino acid at the carboxyl- 
terminus yielded an analogue, [D-Tyr34 ] bPTH-( 1-34)-amide, 270% as active in 
the in vitro renal adenylate cyclase assay as unsubstituted bPTH-(l-34). 
In contrast, placement of a D-amino acid in the amino-terminal region, as 
in the analogues [D-Val2, D-Tyr34]bPTH-(l-34)-amide and [D-Val2, D-Tyr34]bPTH- 
(2-34)-amide, resulted in a nearly complete loss of biological activity. 
Deletion of a single residue at the amino-terminus, as in the analogue 
[D-Tyr34]bPTH-(2-34)-amide, also caused near total loss of biopotency. 
These marked declines in biopotency occurred despite the presence of acti¬ 
vity-enhancing modifications at the carboxyl-terminus of the latter three 
analogues. The most potent of the analogues, [D-Tyr34]bPTH-(l-34)-amide, 
sustained an apparently spontaneous and complete loss of biopotency over a 
period of several weeks. Detailed studies of the mechanism of inactivation 
revealed an unusual lability of methionine residues to oxidation. Reduction 
under controlled conditions restored nearly completely both the methionine 
content and biological activity. 
In order to avoid the oxidation-caused loss of biopotency three sulfur- 
free analogues of parathyroid hormone containing D-amino acids were synthe- 

sized. Norleucine, a sulfur-free non-natural amino acid isosteric with 
methionine, was used. All three analogues were compared in vitro in a 
renal adenylate cyclase assay, a parathyroid hormone receptor binding assay, 
and in vivo in the chick hypercalcemia assay. The analogue [Nle8, Nle38, 
D-Tyr34]bPTH-(l-34)-amide was found to be 440% as potent as unsubsti¬ 
tuted bPTH-(l-34) making this the most potent analogue yet synthesized. 
The enhanced potency was largely attributable to increased affinity for the 
parathyroid hormone receptor. In vivo, however, this analogue was only 
34% as potent as bPTH-(l-34). Cumulative evidence suggests that the 12-fold 
decline in the relative potency when the compound was assayed in vivo is 
due to the substitution of norleucine for methionine. The other analogues, 
[D-Val2, Nle8, Nle18, D-Tyr34]bPTH-(l-34)-amide and [D-Val2, Nle8, Nle18, 
D-Tyr34]bPTH-(2-34)-amide, were only weakly biologically active in the in 
vitro renal adenylate cyclase assay and receptor binding assay and in vivo 
indicating that substitution with D-amino acids at the amino-terminus of PTH 
results in a markedly diminished receptor affinity. The placement of a 
D-amino acid at the amino-terminus is more deleterious to biological acti¬ 
vity than is the ommision of amino acids at positions 1 and 2. These 
results suggest useful directions for further structure-activity studies 
with parathyroid hormone. 
Section II: Canine renal cortical membranes are presumed to contain a 
parathyroid hormone-specific receptor: PTH stimulates adenylate cyclase in 
these membranes and competition for binding sites by a series of hormone 
fragments and analogues has been demonstrated in a radioreceptor assay 
using these membranes. To identify a PTH receptor component in these 
membranes, the sulfur-free synthetic analogue of PTH, [Nle8, Nle38, Tyr34]- 

bPTH-(1-34)-amide, was radiolabelled with Two photolabile aromatic 
azide compounds, 4-Fluoro-3-Nitrophenyl azide and N-Succinimidyl-6(4'-Azido- 
21-Nitrophenyl Amino) Hexanoate, were separately conjugated through lysines 
to different preparations of ^3x-labelled analogue in the dark. Concur¬ 
rently, a corresponding ^^I-labelled analogue was prepared, HPLC purified, 
and demonstrated to be fully biologically active in the in vitro renal 
adenylate cyclase assay. Both radiolabelled photolabile analogues were 
incubated in darkness with canine renal membranes for 45 minutes, in the 
presence or absence of competing hormone, and then exposed to light from a 
high-pressure mercury source to covalently link the analogues to membrane 
components. Membranes were then solubilized and fractionated on SDS-poly- 
acrylamide gels. Radioautographs of the gels were made. In the absence of 
competing hormone, 4-6 membrane components were labelled by each of the 
photolabile analogues. However, only one band labelled specifically: in 
the presence of competing hormone, a membrane component failed to label. 
The position of this band (MW = 70,000) was identical regardless of which 
photolabile analogue was used. This same band labelled in the presence of 
inactive fragments of PTH, but not when competing PTH agonist or antagonist 
analogues were present. Additionally, a porcine renal cell line membrane 
known to have calcitonin-specific adenylate cyclase activity but no PTH- 
specific activity, was incubated and reacted with the photolabile compounds 
with and without competition. Almost no labelled bands were evident, there 
were no changes in the pattern with competition, and the radioautographs 
lacked a 70,000 MW band. These studies identify and will facilitate har¬ 
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or any lengthy tome is being able to thank, in black and white, some of the 
people who helped so much. Dr. Joseph Majzoub I would like to thank for 
his patience in initiating me in the mysteries of gels and radioautographs 
and his unflagging interest in my progress. To Gary Shepard, whom I owe so 
much for massive amounts of help during times I needed five hands and only 
had three, I extend a heartfelt well done. Dr. John Potts, Jr., I want to 
thank for the ideas and dialogues we exchanged over these past three years 
but most of all I want to pay tribute to his assessment of character and 
abilities in matching up people, traits I've come to admire and appreciate. 
And finally to Dr. Michael Rosenblatt, who to me embodied all the above, 
patience, help, and judgement, I say thanks, especially for giving me the 
chance and opportunity that someone once gave him. I certainly hope my 
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Introduction 
Structure-activity relationships have been an important area of 
investigation in hormone research. Through modifications of the naturally 
occurring parent molecule, both enhanced-potency agonist and antagonist 
analogues have been prepared. Indirectly, information about the hormone 
receptor has been obtained in this manner. Such has been the case with 
parathyroid hormone (PTH). Figure 1 depicts the sequences of the three 
parathyroid hormones that have been studied in any detail: bovine, human 
and porcine. Historically, bovine parathyroid hormone (bPTH) occupies the 
most prominent position. First extracted in 1925 from bovine parathyroid 
glands, bPTH has always been the most available owing to its slaughterhouse 
source. In contrast, human parathyroid hormone (hPTH) was originally 
available primarily from adenoma tissue removed during surgery. The full 
structure of human parathyroid hormone was only elucidated in 1978 (20) 
while the bPTH sequence has been known since 1970 (4,33). As a consequence, 
almost all the structure-activity research has been on bPTH and continues 
to be. This thesis concerns itself with the preparation and evaluation of 
bPTH analogues in search of the super-potent analogue, definition of the 
molecular "elbow room" in the receptor, and ultimately the characterization 
of the receptor itself. The first two goals involved the preparation of a 
class of parathyroid hormone analogues incorporating D-amino acids. The 
last goal made use of a related but separate methodology to prepare a 
biologically active photolabile bPTH analogue which was used to tag and 
subsequently separate out the PTH membrane receptor. To adequately discuss 




This thesis summarizes my work over the past three years in the Endo¬ 
crine Unit at Massachusetts General Hospital. I originally sent a letter 
to Dr. John Potts, Jr., head of the unit, inquiring into the possibility of 
working on a synthetic biochemical project for the summer between my first 
and second years at Yale. My letter was forwarded to Dr. Michael Rosenblatt, 
the man I've been associated with these three years. Dr. Rosenblatt, who 
had been working on analogues of parathyroid hormone, was thinking of the 
incorporation of D-amino acids in PTH at that time. With my undergraduate 
background in chemistry, the project was given to me. Out of this first 
summer's work, spanning three and a half months, and numerous discussions 
long after I left, two papers resulted: Analogues of Parathyroid Hormone 
Containing D-Amino Acids: Evaluation of Biological Activity and Stability, 
Coltrera, Rosenblatt, & Potts, Biochemistry (1980) 19, 4380-4385, and; 
Sulfur-free Parathyroid Hormone Analogues Containing D-Amino Acids: Biolo¬ 
gical Activity In Vitro and In Vivo, Rosenblatt, Coltrera, Shepard, 
Gray, Parsons, & Potts, submitted to Biochemistry 1/81. In addition, the 
work covered in the first paper was presented at the Endocrine Society 
meeting in 1979. All the proceedures outlined in Section I were taught to 
me by different people in the Endocrine Unit and performed by myself or 
with the help of others except for the amino acid analyses and the in vivo 
chick hypercalcemia assay which was done by Dr. John Parsons, England. The 
work on the sulfur-free analogues was completed, using my peptides, after I 
had returned to Yale for my second year. 
The successful outcome of the original work encouraged me to tackle 
the more complex problem of finding and characterizing the renal receptor 
for parathyroid hormone. Done over the past six months, the second section 
deals with this work and includes the techniques and protocols developed by 
ii 

me for the syntheses of photolabile PTH analogues and the labelling of the 
PTH receptor. Other techniques new to me were, once again, picked up from 
others in the Endocrine Unit and performed by myself or with help. 
Aside from the successful outcome of my research projects, my asso¬ 
ciation with the Endocrine Unit and Drs. Rosenblatt and Potts in particular 
has been a happy one. I've been exposed to many research techniques as 
well as an invaluable methodology for approaching problems in the medical 





Analogues of Parathyroid Hormone Containing D-Amino Acids 
Part I: 
Substitution of D-amino acids for their naturally occurring L-amino 
acid brethren has produced analogues of several peptide hormones and other 
biologically active peptides that are considerably more potent than their 
native counterparts (5,7,12,15,18,25,29,34,43,50,51,52,61,62). The enhanced 
bioactivity observed for these D-amino acid-containing analogues may be the 
result of one or more mechanisms. Analogous to a key in a lock, alterations 
of the hormonal conformation produced by the inclusion of D-amino acids may 
change the interaction between hormone and receptor (54,63), providing a 
better fit. On the other hand, D-amino acids may make the hormone analogue 
more resistant to enzymatic degradation thus prolonging its survival time 
and availability to the receptor (9,24,36,44). In addition, in the in 
vivo system where renal and other clearance times become a factor, a 
D-amino acid-containing analogue might have a different clearance time than 
the naturally occurring hormone with a subsequent effect on circulating 
hormone levels and availability. 
For bovine parathyroid hormone (bPTH) (Figure 2), the amino acid 
sequence 1 to 34 (starting at the amino terminus) has been found to have 
the structure necessary for the full biological activity of the parent 
molecule, bPTH(l-84) (39,41,59). Further it has been shown that the minimum 
sequence needed for biological activity is 2 to 26 (58). In substituting 1 
to 34 particular attention has been payed to the amino- and carboxyl-terminal 
regions. At both of these areas, marked alterations in bioactivity have 
occurred when these structures have been modified. In particular, certain 
modifications at positions 1 or 34 can produce up to a three-fold increase 
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in biological activity in vitro and in vivo (39,45). Of these, the most 
successful modification to date has been the substitution of tyrosine for 
the phenylalanine in position 34 plus the modification of the carboxyl- 
terminal to an amide (CONH2)• With these facts in mind, an examination 
of the effects on the biological activity by D-amino acid placement in 
either the amino- or carboxyl-terminal region of bPTH(l-34) was undertaken 
Four D-amino acid containing hormone analogues were synthesized by the 
Merrifield solid-phase method (30,31,32): [D-Tyr34]bPTH-(l-34)-amide, 
[D-Val2, D-Tyr34]bPTH-(l-34)-amide, [D-Tyr34]bPTH-(2-34)-amide, and 
[D-Val2, D-Tyr34] bPTH-(2-34)-amide. A single synthesis was branched 
at the appropriate points to produce the four peptides thus minimizing 
variations between them. The biological activity of the analogues was 
evaluated in the in vitro rat renal cortical adenylate cyclase assay 
(21,26,27). 
Materials and Methods 
Synthesis and Purification. Four analogues of bovine parathyroid 
hormone, [D-Tyr34]bPTH-(l-34)-amide, [D-Val2, D-Tyr34]bPTH-(1-34) 
amide, [D-Val2, D-Tyr34]bPTH-(2-34)-amide, and [D-Tyr34]bPTH-(2-34)- 
amide were prepared by a modification (10,46,48) of the solid-phase method 
of Merrifield (30,31,32). The primary structure of the analogues is 
depicted in Figure 3. Synthesis was performed manually in a 50 ml plastic 
syringe fitted with a Luer-Lok drain and a porous polyethylene filter disc 
A mechanical stirrer fitted with a Teflon-coated stirring rod was fixed 
above the reaction vessel. Benzhydrylamine resin (polystyrene-1% divinyl 
benzene, Beckman) was used as the solid support and to effect the carboxy- 
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amide (CONH2) carboxyl-terminal modification. 
The tert-butoxycarbonyl (Boc) group was used to protect *<-amino 
groups during coupling, except for arginine, which was protected by an 
amyloxycarbonyl group. Amino acid side-function protection was obtained as 
follows: (a) the serine hydroxyl group was protected as the O-benzyl 
ether; (b) the tyrosine hydroxyl group was protected as the 0-2,6- 
dichlorobenzyl ether; (c) the carboxyl group of aspartic and glutamic acids 
was protected as the benzyl ester; (d) the histidine imidazole nitrogen and 
the arginine guanidine function were protected by the p-toluenesulfonyl 
group (histidine was stored as the dicyclohexylamine salt and desalted 
immediately before use); (e) the lysine 6-amino group was protected by a 
2-chlorocarbobenzoxy group. L-Amino acids were obtained from Beckman 
Instruments and Peninsula Laboratories; D-amino acids were obtained from 
Bachem Chemicals and Peninsula Laboratories. 
D-Tyrosine was coupled to the benzhydrylamine resin to begin the 
synthesis. Five grams of the copolymer resin (usable nitrogen: 0.51 meq/g) 
was washed (6x) with methylene chloride (CH2CI2) (distilled over potassium 
carbonate) then treated with 30% (v/v) trifluoroacetic acid (TFA) (Pierce) 
in methylene chloride (2x 2 min then 30 min). The resin was then neutralized 
with 10% (v/v) triethylamine (Pierce) in methylene chloride (2x 2 min then 
10 min) followed by washing (4x) with methylene chloride. Coupling of the 
amino acid was done by adding a 2.5 molar excess of B0C-0-2,6-dichloro- 
benzyl-D-Tyrosine and a 2.5 molar excess of dicyclohexylcarbodiimide in 
methylene chloride and stirring for 3 h. The amino acid-copolymer resin 
complex was then washed (6x) with methylene chloride. The unreacted co¬ 
polymer benzhydrylamine groups were then acetylated irreversibly by adding 
2.5 ml acetic anhydride and 0.75 ml triethylamine in 25 ml DMF (20 min). 
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Subsequent amino acids were added in a like manner with the exception of 
arginine and glutamine which were coupled by the "active ester" method. 
For these two amino acids, a 5 molar excess of their respective p-nitro- 
phenyl "active ester" in dimethylformamide was added, stirred 2 h and left 
to react overnight. Figure 4 schematically outlines these steps. After 
incorporation of tryptophan at position 23, 1% mercaptoethanol was added to 
the trifluoroacetic acid reagent and to the TFA-associated methylene chloride 
washes in all subsequent steps in order to minimize oxidation (28). 
Couplings were monitored qualitatively for completeness by the fluor- 
escamine test (11). Double couplings were needed to obtain a negative 
fluorescamine test after the addition of glutamine at 29, leucine at 28, 
lysine at 27, tryptophan at 23, glutamic acid at 22, arginine at 20, and 
methionine at 8. Triple couplings were needed for leucine at 24 and argi¬ 
nine at 25. 
Prior to cleavage, the peptide-resin complex was washed with 30% TFA 
w/1% mercaptoethanol, 1% mercaptoethanol/Ct^C^, CH2CI2 (5x), and 
then shrunk with ethanol and lyophilized. Anhydrous hydrogen flouride (HF) 
was used to simultaneously cleave the peptide from the resin and remove the 
side-chain protecting groups. An excess of doubly-distilled hydrogen 
fluoride was added to the peptide-resin complex along with 7 ml distilled 
anisole (3.5 ml/2.5 g resin) and the reaction was run at 0°C for 1 h. 
Hydrogen fluoride was then removed by reduced pressure distillation. The 
peptide was then extracted by alternating glacial acetic acid and water 
washes (4x each). The washes were combined and lyophilized. 
The crude peptide was taken up in 1 M acetic acid and mounted first on 
a Bio-Gel P-6 column (2.0 x 100 cm) (Bio-Rad Labs). Eluted with 1 M acetic 
acid, the major peak was collected, lyophilized and applied to a carboxy- 
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methylcellulose ion exchange column (CM-52, 1.2 x 15 cm) (Whatman) in the 
presence of 8 M urea. An LKB Ultragrad apparatus was used to create a 
shallow sloped conductance gradient from two ammonium acetate buffers: 1.5 
mmho (pH 5.1) and 20.0 mmho (pH 6.2). The top of the largest peak was 
placed on a Bio-Gel P-2 column (Bio-Rad Labs) for separation of the peptide 
from the urea and ammonium acetate. 
Analytic Methods. Amino acid analyses were conducted with a Beckman 
Model 121 M-B automated analyzer. Acid hydrolysis was performed in 5.7 N 
HC1 at 110°C in an evacuated dessicator for 24 h in the presence of 1:2000 
(v/v) mereaptoethanol to protect the methionine residues (19). Total 
enzymic digestions were performed by using papain (enzyme/substrate ratio 
1:50, pH 5.4, 2 h, 37°C), followed by aminopeptidase M (Henley and Co.) 
(enzyme/substrate ratio 1.5: 1.0, pH 8.2, 3 h, 37°C) in order to correctly 
analyze the labile residues of asparagine, glutamine and tryptophan (41). 
The peptides were analyzed by thin-layer chromatography and thin-layer 
electrophoresis. Two thin-layer chromatography systems using precoated 
cellulose plates (lOOum, Brinkmann) and ninhydrin staining were employed: 
(A) butanol/pyridine/acetic acid/water (15:10:3:12); (B) pyridine/acetic 
acid/water (30:1:270). Two thin-layer electrophoretic systems using 
cellulose-coated plates (lOOum) and ninhydrin staining were employed: (A) 
pyridine/acetic acid/water (30:1:270), pH 6.5 (600 V, 11mA, 1.5 h); (B) 2% 
formic acid and 8% acetic acid, pH 2.0 (600 V, 5-8 mA, 45 min). Sequence 
analyses were performed to quantitate contamination by deletion-containing 
error peptides as well as to confirm the correct amino acid sequence (56,60). 
Reverse-phase high-pressure liquid chromatography was performed with a 
uBondapak column (Waters Associates), two buffers (buffer 1, 20% aceto- 
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nitrile and 80% water with 0.1% trifluoroacetic acid throughout; buffer 2, 
50% acetonitrile and 50% water with 0.1% trifluoroacetic acid throughout), 
a flow rate of 1.5 ml/min, and a linear gradient of 0-100% buffer 2 over 20 
rain (2) . 
Bioassay. Assessment of biological activity in vitro was performed 
using a modification of the rat renal cortical adenylate cyclase assay (21, 
26,27). The incubation mixture consisted of the following: 0.05 M Tris-HCl 
5.4 mM theophylline, 5.4 mM MgC^j 7.8 mM KC1, 0.011% (w/v) bovine serum 
albumin, 0.75 mM ATP, 2 x 10^ cpm of [c<-32p]ATP, 4.5 mM creatine phosphate, 
0.075 mg/ml creatine phosphokinase, and 50 to 100 ug of membrane protein. 
The peptides were added in 5 ul and the total volume was brought to 100 ul. 
Incubations were started by the addition of the membrane suspension and run 
for 10 min at 37°G. Termination was accomplished by the addition of 100 ul 
of a solution consisting of 0.12 M unlabeled cyclic AMP (cAMP), 0.05 M ATP 
and approximately 20,000 cpm of [3p]cAMP in 0.05 mM Tris-HCl. [,?<._32p ] ^TP 
and [3h]cAMP were obtained from New England Nuclear. The bPTH standard 
used in the assays was Medical Research Council Standard, lot no. MRC 
72/286. Each preparation, except [D-Tyr^4]bPTH-(1-34)-amide, was 
assayed at least 3 times at multiple concentrations within 4 weeks of 
completion of purification. Preparations were not treated with reducing 
agents prior to assay, except as described below for a single preparation 
of [D-Tyr-^]bPTH-(l-34)-amide. The individual potency estimates were 
combined to yield the mean potency of each analogue. For [D-Tyr^]bPTH- 
(l-34)-amide, a combined potency determination was not possible because of 
the observed instability of biological activity. 
Reduction of Oxidized [D-Tyr-^]bPTH-(l-34)-amide. [D-Tyr]bPTH- 
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(l-34)-amide (400ug), which had declined to an undetectable level of bio¬ 
activity (presumably due to oxidation), was reduced by treatment with 1.0 ml 
of 0.1 M ammonium acetate (pH 7.4) that was 2 M in mercaptoethanol for 20 h 
at 37°C (65). After treatment, the solution was diluted with 2.0 ml of 
water, placed on a Bio-Gel P-2 column (Bio-Rad) for desalting, then lyo- 
philized and immediately assayed. 
Results 
Analytical Data. Amino acid analysis of each of the four peptides 
is presented in Table I. No heterogeneity of the purified peptides was 
detected in the thin-layer chromatographic or electrophoretic systems used. 
Analytical data for one of the four peptides obtained from the single 
synthesis, [D-Val2} D-Tyr-^]bPTH-(l-34)-amide, are provided. The 
peptide had an Rf = 0.62 in TLC system A and an Rf = 0.81 in system B. 
Electrophoretic mobility relative to leucine was 0.8 in thin-layer electro¬ 
phoretic system A and 1.43 in system B. Accumulated preview^ was determined 
through 30 cycles of automated Edman sequence analysis: the purified pep¬ 
tide contained no more than 4% contamination by deletion-containing error 
peptides (56,60). A high-pressure liquid chromatographic profile of 20 ug 
of [D-Val2} D-Tyr^ ]bPTH-( l-34)-amide is shown in Figure 6. Only a 
small amount of heterogeneity was revealed; contaminants were estimated to 
be <5%. 
Bioactivity. Figure 7 depicts stimulation of rat renal cortical 
membranes in the adenylate cyclase assay by native bPTH-(l-84) (used as the 
assay standard) and the four D-amino acid-containing analogues. [D-Tyr^]- 
bPTH-(1-34)-amide is more potent than native bPTH-(l-84). The other analogues 
' For an explanation of accumulated preview see Figure 5. 
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are only weakly biologically active, and their dose-response curves are non¬ 
parallel to the curve generated by the native hormone standard, indicating 
a qualitative difference in the nature of the observed adenylate cyclase 
stimulation. Mean potencies for each of the analogues are listed and 
compared with the potency of unsubstituted bPTH-(l-34) and a previously 
synthesized (45) highly active PTIl analogue, [ Tyr ^ ] bPTH-( 1-34 )-amide , in 
Table II. Due to the instability of the analogue [D-Tyr^^]bPTH-(l-34)-amide, 
the potency of 14,500 MRC units/mg obtained in the first assay of this 
analogue, 10 days after completion of purification, may actually be an 
underestimate of its true potency. An estimate of its initial potency may 
be derived from an extrapolation of the decreasing biopotencies back to the 
time of synthesis completion. The potency at that time might have been 
18,000 MRC units/mg or greater. 
Instability of [D-Tyr-^]bPTH-(l-34)-amide. A progressive decline 
in biological activity was observed for the analogue [D-Tyr^^]bPTH-(1-34)- 
amide. The peptide had been stored as a lyophilized powder in a closed 
vial in the dark at room temperature. Within 18 weeks of completing the 
synthesis the biopotency had fallen from 14,500 MRC units/mg to an undetect¬ 
able level. Intermediate potencies are plotted as a function of time from 
purification completion in Figure 8. 
Accompanying the loss of biological activity was a complete loss of 
methionine content as determined by amino acid analysis after enzymatic 
hydrolysis. No methionine sulfone was detected at 18 weeks, indicating 
probable spontaneous oxidation of the methionines to the intermediate 
oxidation state of methionine sulfoxide. Reduction of the inactive 
material led to a restoration of 90% of the methionine content and a 
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concomitant restoration of most of the bioactivity. The potency of the 
reduced material was 11,100 MRC units/mg. 
Part II: Sulfur-Free Analogues 
The instability of [D-Tyr34 ]bPTH-(1-34)-amide and its consequent 
rapid decline in biopotency precluded an accurate in vivo assay of the 
compound. Since the mechanism of inactivation was found to be the unusual 
susceptibility of the two methionine residues (at positions 8 and 18) to 
oxidation, a stable analogue using a substitute for methionine was needed. 
Norleucine, a non-natural, sulfur-free amino acid has been substituted for 
methionine previously (46). 
ch2-s-ch2-ch2-ch(nh2)cooh ch2-ch2-ch2-ch2-ch(nh2)COOH 
Methionine Norleucine 
Nearly isosteric with methionine, norleucine was found to be well-tolerated 
in terms of biopotency in vitro. The analogue [Nle8, Nle18, Tyr]bPTH- 
(l-34)-amide had an in vitro biopotency 76% that of unmodified bPTH-(l-34). 
The analogues were stable in long-term storage at room temperature. 
Sulfur-free versions of three of the analogues containing D-amino 
acids were synthesized by the Merrifield solid-phase method (30,31,32): 
[Nle8, Nle18, D-Tyr34]bPTH-(l-34)-amide, [D-Val2, Nle8, Nle18, 
D-Tyr34]bPTH-(l-34)-amide, [D-Val2, Nle8, Nle18, D-Tyr34]bPTH- 
(2-34)-amide. As before, a single synthesis was branched to create the 
three peptides to permit the most valid comparision of biological activity. 
Biological properties were evaluated in the in vitro renal adenylate 
cyclase assay (21,26,27), the PTH-specific renal radioreceptor assay (53), 
and the in vivo chick hypercalcemia assay (38). 
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Materials and Methods 
Synthesis and Purification. The three sulfur-free analogues of bPTH, 
[Nle8, Nle18, D-Tyr34]bPTH-(l-34)-araide, [D-Val2, Nle8, Nle18, 
D-Tyr34]bPTH-(l-34)-amide, [D-Val2, Nle8, Nle18, D-Tyr34]bPTH- 
(2-34)-amide were prepared manually as previously described (see page 2). 
The primary structure of the analogues is depicted in Figure 9. Couplings 
were monitored qualitatively for completeness by the fluorescamine test (11). 
Double couplings were required to obtain a negative fluorescamine test after 
addition of lysine at 26, leucine at 24, and isoleucine at 5. Triple cou¬ 
plings were required for glutamine at 29 and asparagine at 10. After 
double couplings of asparagine at 33, a positive fluorescamine test was 
obtained. At this point, the peptide resin was acetylated to terminate any 
unreacted peptide chains. Purification of the peptides was performed by 
gel-filtration followed by ion-exchange chromatography, as previously de¬ 
scribed (see page 4). 
Analytic Methods. Amino acid analyses as well as thin-layer chroma¬ 
tography (TLC) and thin-layer electrophoresis (TLE) were performed as 
described in Part I (see page 5) with the exception of the TLE systems: (A) 
pyridine:acetic acid:water (30:1:270), pH 6.5; (B) pyridine:acetic acid 
water (1:10:289), pH 3.5. Sequence analyses were again done to quantitate 
contamination by deletion-containing error peptides as well as confirm the 
correct amino acid sequence (56,60). Reverse-phase high-pressure liquid 
chromatography was performed using a uBondapak column (Waters Associates), 
two buffers (Buffer 1: 20% acetonitrile and 80% water-0.1% trifluoroacetic 
acid throughout; Buffer 2: 90% acetonitrile and 10% water-0.1% trifluoro- 
acetic acid throughout), flow rate 1.5 ml/min and a linear gradient of 
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0-100% Buffer 2 over 20 minutes (2). 
Bioassays 
Rat Renal Adenylate Cyclase Assay. Assessment of biological activity 
in vitro was performed using a modification of the rat renal cortical 
adenylate cyclase assay as in Part I (see page 6). The bPTH standard used 
in the assays was Medical Research Council Standard, Lot #MRC 72/286. Each 
preparation was assayed at least three times at multiple concentrations and 
the separate potency estimates were combined to yield the mean potency of 
each analogue. 
Radioreceptor Binding Assay. The parathyroid hormone renal receptor 
binding assay is based on canine renal cortical membranes and a sulfur-free 
radioiodinated PTH analogue ligand 125-£_ [ Nie8 ^ Nle^, Tyr^jbPTH- 
(l-34)-amide (53). Protocols for the preparation of the dog renal cortical 
membranes and the l^I-bPTH analogue may be found on pages 25 and 23 
respectively. 100 to 175 ug of membrane protein and 20,000 to 30,000 cpm 
of 125i_[Nie8, Nle^, Tyr^^]bPTH-( l-34)-amide were incubated in a 
reaction media consisting of 0.05 M Tris-HCl, 9 mM theophylline, 4.2 mM 
MgCl2, 26 mM KC1, 0.118% (w/v) bovine serum albumin, and 5% (v/v) 
parathyroidectomized dog serum for a total volume of 250 ul. The incuba¬ 
tions were run at 15°C for 60 min and the test tubes were gently vortexed 
for a few seconds every 15 min. 200 ul was taken from each test tube 
and placed in 400 ul plastic microfuge tubes (Beckman Instruments, Inc., 
Scientific Instruments Division) which were then spun down at 8000 x g in a 
Beckman microcentrifuge Model 152 (Beckman Instruments, Inc.) for 3 min. 
The supernatant, containing the unbound radioactive ligand, was drawn off 
by a 22 guage lumbar-puncture needle. The tips of the microcentrifuge 
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tubes, containing the spun-down membrane and its bound component of radio¬ 
active ligand, were cut off and counted for a packard /^-well 
spectrophotometer (Packard Instrument Co.). In order to determine the 
total radioactivity added to each incubation tube, controls were run with¬ 
out membranes and, after incubation, a 200 ul aliquot was transferred from 
control to microfuge tube and counted. The 200 ul control aliquots were 
then aspirated and the microfuge tubes were counted for adherence of the 
radioligand to the plastic tube. Losses during incubation were assessed as 
50 ul and this amount was also counted. The total losses were found to be 
constant at 10 * 2% (S.E.M.). 
Each analogue was tested over a concentration range of 1 x 10~^ M 
to 1 x 10"^ M and was assayed at least three times. 
In Vivo Chick Hypercalcemia Assay. The intravenous chick hyper¬ 
calcemia assay (38) was used to assess in vivo biological properties. 
Results 
Analytical Data. Amino acid analysis of each of the three peptides 
is presented in Table III. No heterogeneity of the purified peptides was 
detected in the thin-layer chromatographic or electrophoretic systems 
employed. Analytical data for one of the three peptides obtained from the 
single synthesis, [D-Val^ Nle^, Nle-*-^, D-Tyr-^ ] bPTH-( 1-34 )-amide , is 
provided. The peptide had an Rf = 0.69 in TLC system A and an Rf = 0.8 
in system B. Electrophoretic mobility relative to lysine was 0.71 in TLE 
system A and 0.89 in system B. Accumulated preview^ was determined through 
30 cycles of automated Edman sequence analysis: the purified peptide con¬ 
tained less than 4% contamination by deletion-containing error peptides. A 
^ For an explanation of accumulated preview see Figure 5. 
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high-pressure liquid chromatographic profile of 20 ug of [Nle^, Nle^, 
D-Tyr^^]bPTH-(l-34)-amide is shown in Figure 10. Heterogeneity is esti¬ 
mated to be <2% 
Bioactivity. Figure 11 depicts stimulation of rat renal cortical mem¬ 
branes in the adenylate cyclase assay by native bPTH-(l-84) (used as the 
assay standard) and the three analogues. [Nle^, Nle^, D-Tyr ^ ] bPTH- 
(l-34)-amide is more than four times as potent as native bPTH-(l-84). The 
weighted mean potency of 24,000 MRC units/mg makes this peptide the most 
potent PTH analogue yet synthesized. The other analogues were only weakly 
biologically active and the dose response curves obtained for each of these 
analogues are non-parallel to the curve generated by the native hormone 
standard, indicating a qualitative difference in the nature of the observed 
adenylate cyclase stimulation. Mean potencies for each of the three 
analogues are listed and compared with the potency of unsubstituted bPTH- 
(1-34) in Table IV. 
In vivo biopotencies determined in the chick hypercalcemia assay are 
also listed in Table IV. For the analogue [Nle^, Nle^, D-Tyr-^jbPTH- 
(1-34)-amide, there is a marked disparity between in vitro and in vivo 
biopotency relative to the unsubstituted bPTH-(l-34). Although this ana¬ 
logue has enhanced potency in vitro, approximately 440% as active as bPTH- 
(1-34), the compound is only 34% as active as bPTH-(l-34) in vivo. This 
represents an approximately 12-fold decline in biopotency in the transition 
from in vitro to in vivo bioassay systems. 
The remaining two analogues, [D-Val^ Nle^, Nle-^, D-Tyr^ ] bPTH- 
(l-34)-amide and [D-Val^ Nle^, Mle^, D-Tyr^ ] bPTH-( 2-34)-amide, are 
comparably weak in bioactivity in vitro and in vivo. The weak potency 
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of these compounds can be directly attributed to the decreased affinity for 
the PTH receptor, as demonstrated in the renal receptor binding assay, 
Figure 12. In contrast, [Nle^, Nle^, D-Tyr^ ]bPTH-( l-34)-amide had an 
increased affinity for the receptor. 
Discussion 
Up until now, structure-activity studies of parathyroid hormone have 
followed two general directions. The first has been the identification of 
the functional segments of bPTH and the second has been the substitution of 
naturally occurring amino acids at different positions in the native 
sequence. 
Previous studies have ascertained that the minimum sequence needed for 
full biological activity in vivo and in vitro is 1 to 34 (39,41,59). 
This minimum sequence was found to be further resolvable. The region com¬ 
prising positions 1 and 2 at the amino-terminus is necessary for the acti¬ 
vation of adenylate cyclase once receptor binding had occurred. Distinct 
from the activation region is the sequence 3 to 34 which is largely respon¬ 
sible for the binding to the presumed parathyroid receptors (14,47,49). The 
sequence 3 to 34 forms the basis for the present inhibitor designs. Figure 
13 illustrates these regions in bPTH. The terminal sequence 25 to 34 has 
been found to contain the structural features most important for the 
receptor binding(35). 
Substitution of naturally occurring amino acids at position 1 in the 
1 to 34 sequence by Tregear & Potts (57) has shown that even subtle alter¬ 
ations in the structure there led to large variations in the biopotency of 
bPTH. Generally, position 1 alterations represent decreases in bioactivity. 
Certain modifications at the carboxyl-terminus, the phenylalanine at posi- 
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tion 34, yielded analogues of enhanced activity. Substituting tyrosine for 
phenylalanine produced an analogue 140% as active as unsubstituted bPTH- 
(1-34) (46). The modification represents the addition of one hydroxyl 
group on the phenyl ring. Converting the carboxyl-terminal carboxylic acid 
function [-C00H] to a carboxyamide [-CONH2] produced an analogue which 
was 270% as potent as bPTH-(l-34) (39). The analogue [Tyr^JbPTH- 
(l-34)-amide, which combines both of these modifications, was found to be 
almost 300% as active as bPTH-(l-34) (45). 
The approach chosen here was to incorporate, for the first time, non¬ 
natural amino acids to pursue another possible design form for analogues. 
While the carboxyl-terminal binding region had tolerated modifications well 
in the past, modifications at the amino-terminus (the activation region) 
had shown the position 1 alanine to be a highly critical feature. Therefore 
position 2, valine, was chosen as the best sight for D-amino acid substi¬ 
tution in the amino-terminal region. 
The rat renal adenylate cyclase assay was chosen for biological eval¬ 
uation of all the analogues in vitro. The dog renal assay was also avail¬ 
able for the evaluation of the sulfur-free analogues but there were distinct 
advantages to using the rat renal assay again. First, this choice allowed 
direct comparison with the original sulfur-containing D-amino acid 
analogues. Secondly, the rat renal membrane preparation is relatively rich 
in enzymes that degrade PTH whereas the dog renal membrane preparation is 
cleaner and therefore more sensitive and thus is now the preferred assay. 
But part of the argument for trying D-amino acid incorporation was the 
possible resistance to enzymatic degradation this might confer on the 
molecule. The rat renal assay could be useful as a screening assay for 
such attributes. The highly purified dog renal membranes were used in the 
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renal radioreceptor assay. This assay provides a measure of the inter¬ 
action of analogues with the PTH-specific renal receptors. To complete the 
biological evaluation with an in vivo study, the chick hypercalcemia 
assay was used. The hypercalcemia caused by intravenous PTH-like agonists 
is felt to be a reflection in large part of the biological action of PTH on 
the bone. In the past there has been a very close correlation between an 
analogue's in vitro and in vivo biological properties (39,58). 
Studies reported here confirmed that modifications at the amino- 
terminal activation region were poorly tolerated in terms of biopotency. 
With D-Val in place of L-Val in position 2, there was a nearly complete 
loss of bioactivity in the in vitro adenylate cyclase system for both 
[D-Val2, D-Tyr34]bPTH-(l-34)-amide and [D-Val2, D-Tyr34]bPTH-(2-34)- 
amide. This loss of potency occurs in the face of the activity-enhancing 
D-Tyr34-amide modification at the carboxyl-terminus. Simple deletion of 
position 1 in [D-Tyr34]bPTH-(2-34)-amide resulted in a similar near total 
loss of biological activity (Table II). 
Conversely, substitution of D-Tyr at the carboxyl-terminus of 1 to 34, 
is well tolerated. The analogue produced, [D-Tyr34]bPTH-(1-34)-amide, is 
nearly equal in biopotency to the most active analogue produced before, 
[Tyr34]bPTH-(l-34)-amide (Table II). Over a period of 18 weeks, however, 
the activity in vitro was completely lost corresponding to a progressive 
oxidation of both methionine residues (positions 8 and 18) in the molecule. 
Evaluation of the in vivo biological activity was not possible because 
of the instability of the molecule. Oxidation of methionine has been 
previously found to result in complete loss of PTH activity (37,40,42,55). 
Spontaneous decline in the biopotency of the larger native molecule bPTH- 
(1-84) has been seen to occur over a period of months to years (observed 
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in the Endocrine Unit, MGH). Similarly, other enhanced-potency analogues 
have lost differing amounts of bioactivity when stored in light protected 
containers, but the loss in [D-Tyr34]bPTH-(l-34)-amide was much faster 
and more complete than any other. Back reduction of the methionines 
resulted in a regaining of 90% of the biological activity previously 
demonstrated. But it was obvious that, lacking a storage method utilizing 
reducing atmospheres or agents, the full biopotency of [D-Tyr34]bPTH- 
(l-34)-amide had not been measured, the first assay being performed 10 days 
after purification. 
For this reason sulfur-free, oxidatively-stable analogues containing 
D-amino acids were made. Once again, substitution of D-Val for L-Val in 
position 2 was poorly tolerated with an in vitro biopotency of <2% of 
bPTH-(1-34) for both [D-Val2, Nle8, Nle18, D-Tyr34]bPTH-(1-34)-amide 
and [D-Val2, Nle8, Nle38, D-Tyr34]bPTH-(2-34)-amide. In vivo 
assay of the two peptides also showed activity <2% that of bPTH-(l-34). 
These results could also be correlated with the observed decreased binding 
to the receptor (Figure 12). 
In contrast, the analogue [Nle8, Nle38, D-Tyr34]bPTH-(l-34)-amide 
was found to be more than fourfold as active as unsubstituted bPTH-(l-34) 
in vitro making it the most potent PTH analogue yet synthesized. This 
increased bioactivity in vitro correlated with an increased affinity 
for PTH-specific binding sites. The previous observation that [Nle8, 
Nle38]bPTH-(1-34) is only 45% as potent as bPTH-(l-34) in vitro (46) 
suggests the obvious generalization that the substitution of norleucine for 
methionine, while bestowing oxidative resistance on an analogue will also 
generally decrease their biopotency. If this is so, then [D-Tyr34]bPTH- 
(l-34)-amide would be expected to have a biopotency even greater than [Nle8, 
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Nlel8, D-Tyr34]bPTH-( l-34)-araide and very likely significantly higher 
than originally estimated. 
In vivo, norleucine substitution is more poorly tolerated. [Nle8, 
Nle38]bPTH-(1-34) has an activity in vivo of 1800 MRC units/mg ^ 
compared with a bPTH-(l-34) standard of 7700 MRC units/mg. [Nle8, Nle^8, 
Tyr34]bPTH-(l-34)-amide with its activity-enhancing carboxyl-terminus 
modifications has an in vivo activity of 2500 MRC units/mg^. [Nle8, Nle38 
D-Tyr34]bPTH-( l-34)-amide follows a similar pattern. In vitro it is 
more than 400% as potent as bPTH-(l-34) but in vivo it is only one-third 
as active as bPTH-(l-34). With an in vivo potency of 2600 MRC units/mg 
it still stands as the most potent of the norleucine containing analogues. 
In comparison to [Nle8, Nle^8, D-Tyr34]bPTH-( l-34)-amide, the two 
D-Val norleucine-containing peptides resulted in a decline in bioactivity. 
The two analogues, [D-Val3} Nle8, Nle38, D-Tyr34]bPTH-( l-34)-amide and 
[D-Val2} Nle8, Nle38, D-Tyr34 ]bPTH-( 2-34)-amide, were <2% as active as 
bPTH-(l-34) in vivo. Apparently the altered conformation created by the 
D-amino acid placement in the amino-terminus is responsible for this de¬ 
cline. Furthermore, whereas the in vitro radioreceptor binding assay 
showed that placement of the D-amino acid at the carboxyl-terminus is 
actually affinity enhancing, placement of a D-amino acid in the amino- 
terminal region causes a decrease in receptor affinity of approximately 
30-fold. In point of fact, placement of a D-amino acid in the amino-termi 
nal region seems worse for bioactivity than the complete omission of the 
terminus (positions 1 and 2): the compound [Nle8, Nle38 ,Tyr34]bPTH-( 3-34)- 
amide which is missing positions 1 and 2 is equal in binding affinity to 
[Nle8, Nle18, Tyr34]bPTH-(l-34)-amide (35,53) and in vivo bPTH(2-34) is 
^Parsons, J.A., Tregear, G.W., & Rosenblatt, M. unpublished results. 
-18- 

approximately 50% as potent as bPTH-(l-34) (39,58). 
In summary, both in vitro and in vivo studies show that D-amino 
acid substitutions critically affect biological properties. Whether the 
effect is positive or negative depends on their position. The amino- 
terminus is virtually intolerant of such substitutions while the carboxyl- 
terminus tolerates them well. [Nle^, Nle^^, D-Tyr^]bPTH-(1-34)-amide 
with a biopotency of 24,000 MRC units/mg in vitro is the most potent 
PTH analogue yet made. But what may be an in vivo intolerance to 
norleucine has precluded an accurate in vivo appraisal of the hoped for 
benefits of D-amino acids. So, while placement of D-amino acids in the 
carboxyl-terminal region of the 1 to 34 fragment appears very promising, 
their in vivo evaluation must await either development of storage 
conditions to preserve the biological activity and methionine content or 
the synthesis of sulfur-free oxidatively-stable PTH analogues with higher 





Photoaffinity Labelling of the Parathyroid Hormone Receptor 
As previously noted, PTH analogues can supply information about the 
membrane receptor in addition to their relative merits as synthetic 
replacements for native PTH-(l-84). This approach is an indirect one in 
that it gathers information without actually finding the receptor. 
However, the advantages to finding the receptor itself are obvious. In a 
highly purified form its biochemical structure as well as its physiologic 
properties would be easier to elucidate. Immunologic studies would be 
facilitated, especially the development of monoclonal antibodies, a current 
research problem. Purified receptor could also form the basis of a very 
sensitive radioreceptor assay. This section deals with the development of 
biologically active bPTH analogues used to tag the parathyroid hormone 
receptor in renal cortical membranes and the subsequent separation and 
identification of the receptor/receptor subunit from the membrane. 
The Rationale 
In approaching the problem of finding any receptor, hormonal or other¬ 
wise, the receptor must be tagged in an identifiable manner and this tag 
retained during the purification steps. Various approaches have been used, 
including radioactively labelled antibodies to a receptor, and gel columns 
impregnated with substances that have differing affinities for the receptor 
and other proteins. The approach that has been among the most versatile, 
and in the long run will probably prove to be the most successful, is photo¬ 
affinity labelling. 
Basically, the problem of receptor labelling can be stated this way: 
the label must be highly specific for the receptor or the result would be 
useless. Few things have a greater specificity for the receptor than the 
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hormone itself, making PTH the ideal vehicle for tagging the receptor. With 
the advent of a radiolabelled, biologically active bPTH analogue, 1 I- 
[Nle^, Nle^, Tyr^]bPTH-( 1-34)-amide (46,53), a way to tag and follow 
the PTH receptor was available. If a covalent linkage could be formed 
between PTH and its receptor, then the hormone-receptor complex could be 
separated from the membrane and characterized by following the radioactive 
label. To achieve the linkage between hormone and receptor, a group 
capable of activation and reaction while the hormone is in the receptor 
must be attached to the hormone while retaining the hormone's bioactivity 
and specificity. Photoactivated groups have a distinct advantage in ease 
of activation while maintaining control over time and place. A number of 
very reactive groups are available and have been used to label several dif¬ 
ferent receptor systems, most notably insulin, glucagon and acetylcholine 
(3,6,16,64). 
The photoactive ligand must incorporate both the photolabile group 
used to effect the linkage between hormone and receptor, and a more 
conventional reactive group for attachment to the hormone. The most common 
hormonal attachment site has been a primary amine group. Attributes needed 
for the photolabile group itself include chemical stability before 
activation, activation energy absorptions at long enough wavelengths or 
short enough periods of time to preclude photochemical damage (i.e. oxida¬ 
tion) to the rest of the system, extremely short half-life, high reactivity, 
and resistance to intramolecular rearrangements which could result in less 
active forms (1). Among the choices for photolabile groups, aryl azides 
have proved to possess a good compromise of qualities. The azide, (N^), 









The nitrene, though less reactive than its carbon equivilent, the carbene, 
is capable of reacting with primary, secondary, and tertiary carbon- 
hydrogen bonds (C-H) as well as hydroxyls (0-H). Once activated, it will 
react with whatever is in its immediate proximity. Owing to the specificity 
of PTH, there is a high probability that the nitrene's neighboring proteins 
will include the receptor. Non-specific binding could be differentiated 
from specific binding through the use of cold hormone as competition with 
the photolabile analogue. Only the PTH-specific binding, i.e. the receptor, 
would be affected. 
Two photolabile aryl azide-containing compounds were chosen for 
attachment to the 125-j- labelled PTH analogue. 
(1) 4-Fluoro-3-Nitrophenyl Azide (FNPA) 
(2) N-Succinimidyl-6(4'-Azido-2'-Nitrophenyl Amino) Hexanoate (SMHA) 
Both groups will react with primary amines under relatively mild conditions. 
The only available primary amine groups in 1 to 34 are the lysine £-amino 
groups at positions 13, 26, and 27, and the position 1 alanine ' s o<-amino 
group. Any addition to the position 1 alanine would probably result in an 
inactive analogue (see page 14) (57). But the ^-amino groups on lysine are 
normally much more reactive than the valine °<-amino group and as long as 
the peptide's conformation does not totally block these groups the chances 
are good that this attachment will be the favored one. 
The analogues, FNPA-^^I-[Nle^, Nle^, Tyr^]bPTH-( l-34)-amide and 
SMHA-^^I-[Nle®, Nle^, Tyr^]bPTH-( l-34)-amide, were evaluated sep¬ 
arately with dog renal membrane preparations. High-pressure liquid chroma¬ 
tography purified (HPLC) FNPA-^^I-[Nle^ , Nle^, Tyr^ ] bPTH-( 1-34 )-amide 




Materials and Methods 
Synthesis and Purification of [Nle®, Nle*®, Tyr^]bPTH-( 1-34)-amide. 
The basic peptide was synthesized by the Merrifield solid-phase method 
and purified as previously outlined (see page 2). 
Iodination. [Nle^, Nle^, Tyr^ ] bPTH-( l-34)-amide was iodinated 
by a modified Hunter and Greenwood protocol (17). The reaction was run at 
room temperature in a 0.2 M sodium phosphate buffer (pH 7.5) using a molar 
ratio of hormone/l“/Chloramine-T (Eastman Chemical) of 1:1.5:200. After 
30 sec the reaction was stopped by the addition of sodium metabisulfite in 
a 2-fold molar excess to Cloramine-T. 
For the radiolabelling of the peptide, Na^^I (New England Nuclear) 
was used in a protocol calling for 1500 uCi per 2 ug of bPTH-(l-34) (46). 
8 ug of [Nle®, Nle^, Tyr^] bPTH-( l-34)-amide (1.9 nmol) was dissolved in 
40 ul of 0.1 N HOAc and added to 200 ul of 0.2 N sodium phosphate buffer 
along with 6 mCi of Na^^I. Chloramine-T ( 380 nmol) in 40 ul buffer was 
added and allowed to react for 30 sec. The reaction was stopped with sodium 
metabisulfite (760 nmol) and a small amount was drawn off to check for ^^1 
incorporation. 1 ml of H2O was added along with approximately 1 cc of 
QUSO-32 (Philadelphia Quartz Company) to adsorb the peptide. The sample 
was centrifuged and the supernatant was discarded. Excess 1 JI was 
removed by the addition of 1 ml H2O and I-resin, centrifuging and discar¬ 
ding the supernatant. 1 ml of 20%:1% acetone/glacial acetic acid was then 
added, the pellet resuspended, spun down and the supernatant drawn off and 
lyophilized. 
A non-radioactive labelling of 2 mg [Nle^, Nle^, Tyr^jbPTH- 
(l-34)-amide was done for use in the in vitro bioassay of the photo- 
-23- 

affinity compound. KI was used and trace amounts of were added 
to check for incorporation. After neutralization with sodium metabi¬ 
sulfite the reaction was lyophilized. The lyophilized product was then 
dissolved in <1 ml of 0.1 M HOAc in 8 M urea and placed on a Bio-Gel P-2 
column (41 x 1.2 cm) previously equilibrated with 0.1 M HOAc. The peptide 
eluted in the void volume followed by Chloramine-T, metabisulfite, and 
iodine (Figure 14). The peptide was lyophilized and stored for further 
use. 
Attachment of the Photolabile Groups. (1) 4-Fluoro-3-Nitrophenyl Azide 
(FNPA): 2 ug 125-]-_[N;Le8 ^ Nle-^, Tyr^ ] bPTH-( 1-34)-amide (478pmol) was 
dissolved in 100 ul DMSO. A 20-fold excess of FNPA (9.56 nmol) (Pierce) in 
25 ul DMSO was added along with 1 x 10~9 mol triethylamine. The reaction 
was protected from light and agitated continuously at room temperature for 
5 h. A 400-fold excess of glycine (191 nmol) was added to terminate the 
reaction. 
(2) N-Succinimidyl-6(4'-Azido-2'Nitrophenyl Amino) Hexanoate (SMHA): 2 ug 
125i_[jjie8^ Nle^, Tyr^ ]bPTH-( l-34)-amide was dissolved in 100 ul 0.2 M 
sodium phosphate buffer, pH 7.5. A 20-fold excess of SMHA (9.56 nmol) 
(Pierce) in 20 ul buffer was added. The reaction was protected from light 
and agitated continuously for 1 h at room temperature. A 400-fold excess 
of glycine (191 nmol) was added to terminate the reaction. 
The reaction products in both cases were stored at 4°C in the dark 
and used without further purification. The primary structure of the ana¬ 
logues is depicted in Figure 15 along with the photolabile groups. 
FNPA-127[nie8} Nle^®, Tyr~^]bPTH-(l-34)-amide was also prepared 
in a scaled up FNPA synthesis for 2 mg of peptide for use in a representive 
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bioassay and analyses. 
Analytic Methods. Reverse-phase high-pressure liquid chromatography 
was performed with a uBondapak column (Water Associates), two buffers 
(buffer 1, 5% acetonitrile and 95% water with 0.1% trifluoroacetic acid 
throughout; buffer 2, 90% acetonitrile and 10% water with 0.1% trifluoro- 
acetic acid throughout), a flow rate of 2.5 ml/min, and a linear gradient 
of 0-100% buffer 2 over 30 min (2). Spectroscopic analysis was done with a 
Beckman Model 25 Spectrophotometer on material from the preparative HPLC. 
Renal Cortical Membrane Preparation. Kidneys were obtained from 
healthy mongrel dogs weighing between 20 and 27 kg. The membranes were 
prepared following a modified method (53). The cortex was bluntly dis¬ 
sected from the medulla and homogenized at 4°C in a 30% buffer solution 
containing 0.25 M sucrose, 0.01 M Tris, and 0.001 M Na2EDTA, pH 7.5. The 
tissue was diluted 1:1 with the buffer solution and centrifuged by 
accelerating the rotor to 2200 x g and immediately decelerating it. The 
supernatant was collected and respun in the same manner after which it was 
again collected and spun at 2200 x g for 15 min. The supernatant was then 
discarded and the resulting "double-layered" pellet was resuspended in the 
same buffer as before, homogenized and again spun at 2200 x g for 15 min. 
The supernatant was discarded and the pellet was resuspended in a small 
amount of buffer solution. The suspension was then layered onto discon¬ 
tinuous gradients of sucrose in 0.01 M Tris, 0.001 M Na2EDTA, pH 7.5. 
The gradients consisted of 39% sucrose (3 ml), 37% sucrose (6 ml), and 32% 
sucrose (2 ml). The membranes were then centrifuged at 75,000 x g for 90 
min at 4°C. Following this there were major bands present at all inter¬ 
faces as well as a pellet. The small amount of protein that doesn't enter 
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the sucrose and the material found at the 37% sucrose interface have ident¬ 
ical PTH-stimulated adenylate cyclase activity and binding characteristics, 
so the two were combined by aspirating with a Pasteur pipette. The material 
at the 39% interface binds PTH very poorly and was discarded. The combined 
materials from the 32% and 37% interfaces were diluted in three volumes of 
a buffer solution consisting of 0.01 M Tris, 0.001 M Na2EDTA, pH 7.5, and 
then centrifuged at 7800 x g for 15 min to remove the sucrose. The pellet 
was then resuspended in 0.05 M Tris, pH 7.5 and split up into 1 ml aliquots 
which were centrifuged at 2200 x g for 15 min, the supernatants discarded, 
and the pellets stored at -70°C. 
Dog Renal Adenylate Cyclase Assay. The incubation mixture consisted 
of the following: 0.05 M Tris-HCl, 0.84 mM ATP, 0.08 to 2.0 x 10^ cpm of 
[c<-^P]ATP, 9 mM theophylline, 4.2 mM MgCl2> 26 mM KCl, 0.118% (w/v) 
bovine serum albumin, 5 mM creatine phosphate (Schwarz/Mann Division, 
Becton-Dickenson & Co.), 0.1 mg/ml of creatine phosphokinase, and 40 to 90 
ug of membrane protein (53). FNPA-^^I-[Nle^ , Nle^, Tyr ] bPTH-( 1-34 )-amide 
was added in 5 ul and the total volume was brought to 100 ul. Incubations 
were started by addition of the membrane suspension and run for 10 min at 
37°C. Termination was accomplished by the addition of 100 ul of a solution 
consisting of 0.125 M unlabeled cAMP, 0.04 M ATP, and approximately 20,000 
cpm of [^H]-cAMP in 0.05 mM Tris-HCl at pH 7.4. The reaction mixture was 
then boiled for three minutes to assure termination. The [^p]-cAMP 
generated was then separated from the other [^2p]-containing reaction 
by-products through ion-exchange chromatography on columns of Dowex 50 W-X4 
(H+ form; 200-400 mesh, J.T. Baker Chemical Co.) followed by columns of 
alumina. Protein concentration was determined by the method of Lowry et al 
-26- 

(23) with bovine serum albumin as standard. 
The bPTH standard used in the assays was Medical Research Council 
Standard, lot no. 76/372. Each peptide was assayed twice at multiple con¬ 
centrations . 
Photoreaction of Membranes and Photolabile Analogues. 100 ug 
aliquots of dog renal membrane were suspended in 100 ul of a reaction 
buffer consisting of 0.05 mM Tris-HCl, 9 mM theophylline, 4.2 mM MgCl2> 
26 mM KCl, 0.118% (w/v) bovine serum albumin, and placed in 12 x 75 mm 
glass test tubes in a 15°C water bath. To the tubes which were to contain 
competing peptides, 10 ug of the appropriate peptide was added and preincu¬ 
bated for ten minutes. Total volume of these tubes was then brought to 200 
ul by addition of 100 ul of buffer solution. In the dark, 1.2 x 10^ cpm 
of radioactive photoaffinity-labelled peptide was added to each test tube 
and incubated for 45 rain. The test tubes were vortexed gently every 15 
min. The total volume of the remaining tubes was brought to 200 ul and all 
the tubes were then exposed for 20 min to a high-pressure mercury vapor 
lamp at 12 inches. After centrifuging the tubes at 2250 x g, 4°C for 4 
min, the supernatant was aspirated. The pellets were resuspended in a 
solution consisting of 75 ul water, 25 ul 10% SDS, and 25 ul of a sample 
buffer. The sample buffer consisted of 5 ml glycerol, 1 g SDS, 2.5 ml 
/?-mercaptoethanol, 0.25 ml of 0.2% bromphenol blue in double distilled 
water and 2.5 ml of a stock solution made by dissolving 3 g Tris-Base in a 
total volume of 25 ml of water, pH 6.8. The suspensions were then boiled 
for 2 min and mounted immediately on SDS-acrylamide gels. 
Electrophoresis in Sodium Dodecyl Sulfate-Polyacrylamide Gels. SDS- 
acrylamide 9 - 20% gradient gels (10 x 15 x 0.15 cm) were prepared by the 
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method of Laemmli (22). 25 ul aliquots of the membrane suspensions were 
mounted in each lane. Marker proteins were run in separate lanes. The 
SDS-acrylamide gels were run at constant voltage till the bromphenol blue 
stacking line reached the bottom. After electrophoresis the gel was stained 
with Coomassie blue and destained, then dried down and mounted for 
radioautography on Kodak X-Ray Film Type SB-5. 
Results 
Analytical Data. Data are presented for the preparative run of FNPA- 
^^I-[Nle®, Nle^, Tyr^]bPTH-( l-34)-amide used in the adenylate 
cyclase assay. HPLC was used to separate the photolabelling-reaction 
products. Two peaks from this HPLC consisted of FNPA-labelled peptide. 
Material from both peaks was analysed spectroscopically and the azide 
group's absorptions were normalized with respect to the relative amounts of 
peptide bond absorptions in lieu of known ligand concentrations. A ratio 
of 2:1 was found, most probably corresponding to a like number of FNPA- 
lysine amino group bonds per peptide molecule (total of three lysines per 
peptide). Material from Peak 1 (the most abundant, with a single FNPA per 
molecule) was reinjected for an analytical HPLC run to check for impurities. 
( 1) -FNPA-^I-[Nle® , Nle-*-, Tyr~^]bPTH-( l-34)-amide is shown in Figure 16 
from the analytical run. Heterogeneity was estimated as less than 1%, 
showing this peptide to be pure when used in the adenylate cyclase assay. 
Figure 16 is a composite HPLC chart to illustrate the relative elution 
points of [Nle^, Nle^®, Tyr^]bPTH-( l-34)-amide, ^^I-[Nle®, Nle^, Tyr^] 
bPTH-( 1-34)-amide , and the FNPA-^^I-labelled peptide. 
Bioactivity. Both peaks from the preparative HPLC were assayed twice 
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in the dog renal adenylate cyclase assay. Calculated potencies for (l)-FNPA- 
12^I-[Nle®, Nle^®, Tyr-^]bPTH-( l-34)-amide were 24,300 MRC units/mg 
and 30,800 MRC units/mg. With a mean potency of 26,000 MRC units/mg (95% 
confidence limits: 22,000 - 30,800), this photolabile PTH analogue is quite 
active. In fact these preliminary figures make it the most potent PTH ana¬ 
logue yet made^. Potency values for (2)-FNPA-^^I- [Nle^, Nle^, Tyr-^]- 
bPTH-(l-34)-amide were 5600 MRC units/mg and 11,600 MRC units/mg respec¬ 
tively. Though not as potent as (l)-FNPA, (2)-FNPA, with two FNPA-lysine 
amino bonds, is still more potent than the native hormone bPTH-(l-84). 
SDS-Acrylamide Gel Radioautographs. Coomasie blue staining of the 
gels reveal many protein bands. Of these, there are five to six distinct 
bands visible on the radioautograph, Figure 17. Lane 1 consists of the 
membrane/photoligand reaction without competition. Lane 2 is with 10 ug 
[Nle^, Nle^, Tyr^]bPTH-( l-34)-amide as competition. One band 
disappears in Lane 2. Using the known weights of the marker proteins, the 
weight of any unknown protein band can be calculated as follows: for the 
ratio d/L where L is the gel lane length and d is the distance traveled 
through the gel by the protein band, a plot of the log of the molecular 
weight vs d/L will be linear. The d/L of the unknown is plotted along 
the "known" graph to find the molecular weight. Figure 18 shows the line 
plots for two gels; one with FNPA-^^I-[Nle^, Nle^®, Tyr^jbPTH- 
(l-34)-amide and the other with SMHA-^^I-[Nle^, Nle^, Tyr^]bPTH- 
(l-34)-amide. In both cases the weight of the unknown band which competes 
out is 70,000 - 1000 Daltons. This same band is extinguished with the 
addition of inhibitor but is unaffected by inactive fragments of bPTH. 
^[Nle®, Nle^®, D-Tyr^]bPTH-( l-34)-amide held that distinction in Section 




Receptors have long been studied at arm's length by manipulating the 
hormones that interact with them, the cells that sprout them, and their 
working conditions. With the recent advent of labelling techniques capable 
of tagging a receptor, the research takes on the new emphasis of actually 
finding the receptor. 
For parathyroid hormone a photoactive group was chosen for its 
advantages in activation and controllability. In selecting the photoactive 
group, the aryl azides were among the most commonly used in other hormone 
photolabelling systems(1,6). The attributes of the azide moiety include a 
fast conversion to the reactive intermediary, the nitrene, and a lack of 
intramolecular rearrangements to less reactive forms. These two factors 
are crucial in that they determine the efficiency of the reaction and, 
ultimately, the reproducibility of the results. Fast conversion also means 
less exposure to the intense irradiation that may damage other components 
of the photolabelling system. The nitrene intermediary is capable of 
reacting with all types of carbon-hydrogen bonds and hydroxyl bonds, all of 
which are abundant in a protein receptor. 4-Fluoro-3-Nitrophenyl Azide 
(FNPA) and N-Succinimidyl-6(4'-Azido-2'-Nitrophenyl Amino) Hexanoate (SMHA) 
were chosen for their ease of attachment. Both react with primary amines 
under relatively mild conditions. The two groups had advantages and dis¬ 
advantages. Succinimide being the better leaving group, SMHA attachment 
to bPTH was more certain than FNPA but its hexanoate group was much bulkier 
than the phenyl ring of FNPA and this was a possible liability in producing 
a bioactive PTII ligand. To increase the chances of success, both were 
synthesized. In the event that both ligands were active they should label 




With the choice of photolabile group made, it remained to be proven 
that it would attach to PTH and, once attached, would not interfere with 
PTH's bioactivity, re specificity for the receptor. A scaled-up syn¬ 
thesis of FNPA-127I-[Nle®, Nle^, Tyr^]bPTH-( l-34)-amide was made as 
a representative check for azide incorporation and bioactivity. After 
completion of the synthesis, the entire reaction mixture was injected in an 
HPLC and the peaks were collected in the dark. Two large peaks, close 
together and early in the reverse-phase run, were collected separately and 
found to contain peptide with FNPA. To demonstrate the homogeneity of the 
material used in the in vitro assay an analytical HPLC run was per¬ 
formed on material from the first peak (Figure 16). The peptides were 
analyzed spectroscopically by hand. Since both peptides had the same 
molecular extinction coefficients for the amino acid backbone the relative 
concentrations of the two samples could be used to normalize the azide 
absorptions. When this was done, the second peak was found to have twice 
the azide absorbance per molecule of peptide peak 1. In the bPTH 1 to 34 
sequence there are only four possible attachment points: the-amino group 
on the position 1 alanine and the ( -amino group on the three lysines (posi¬ 
tions 13, 26, and 27). Amino acid analysis was not helpful in ruling out 
the position 1 alanine since the FNPA-amino bond proved to be labile under 
the conditions employed (5.7 N HC1 at 110°C for 24 h), but an FNPA-Ala^ 
attachment was considered unlikely in this material due to its enhanced 
bioactivity. Any deliberate modifications of position 1 have decreased or 
destroyed the potency of PTH—(1-34) in the past (57). With three lysines, 
in each peptide a 1:2 ratio of absorbances suggests 1 FNPA/peptide and 2 
FNPA/peptide for (1)-FNPA-127I-bPTH and (2)-FNPA-127I-bPTH respectively. 
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Edman sequencing may prove useful in finding which positions were substi¬ 
tuted. In the in vitro dog renal adenylate cyclase assay (1 )-FNPA-^^I- 
bPTH had a markedly increased potency of 30,800 MRC units/mg in the first 
assay and 24,300 MRC units/mg in the second. While not nearly as active, 
(2)-FNPA-127 j-bp-jH was still more potent than unsubstituted bPTH-(l-34). 
A similar preparation and analysis was not done with SMHA-bPTH. Since the 
radioactive preparation labels the same bands as FNPA it must be assumed to 
have retained its biological activity also. 
A slightly different protocol was used in the preparation of the 
labelled photolabile PTH analogues because of the small amounts 
of peptide used (2 ug) and the radioactivity. QUSO-32 was used to separate 
125i_pth after iodination instead of a P-2 column. More significant 
a change was the use of the reaction mixture from the photolabelling 
without purification. Since the unreacted and partially reacted by¬ 
products would lack the crucial combination of both photolabel and 125^ 
and thus would not affect the radioautographic bandings or the specificity 
of the FNPA and SMHA 125j- labelled analogues, purification was not 
necessary. 
The biospecificity of the analogues was checked by using both 
competitive antagonists and agonists with inactive fragments as controls. 
These included [Nle8, Nle18, Tyr3^]bPTH-(l-34)-amide (agonist), [Nle8, 
Nle18, Tyr]bPTH-(3-34)-amide (antagonist), bPTH-(53-84) (approximate 
size inactive fragment), and bPTH-(l-12) with bPTH-(13-34) (full sequence in 
fragments). Of the many protein bands on the Coomasie blue-stained gel, 
only four to six were distinctly labelled on the radioautograph. One band, 
at molecular weight 70,000, disappeared when competing amounts of agonist 
were added. This same band was unaffected by inactive fragments of bPTH 
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but was eliminated by antagonist as well. In addition, porcine renal cor¬ 
tical membranes (cell line LLC-PK-^), which were known to be responsive to 
calcitonin but unresponsive to PTH (13), were labelled resulting in a dif¬ 
ferent radioautographic pattern almost devoid of bands which was unchanged 
with addition of agonist and lacked a 70,000 weight band. Non-specific 
binding of the ligand to albumin, which is in the same weight range and 
present in the membrane preparation, was also ruled out by labelling heat- 
inactivated serum albumin and running it in a separate lane on the gel. 
From the evidence available, it appears that the labelled band at 
70,000 molecular weight is the parathyroid hormone receptor or at least a 
receptor subunit. The 9 - 20% SDS-acrylamide gel used is generally capable 
of resolving proteins in the 10-13,000 to 120,000 weight range. Within 
that range there do not appear to be any other competable bands. To be 
more complete, other gels should be made to look for protein bands at 
higher and lower weights as well as improve the resolution at the upper and 
lower limits of the 9 - 20% gels. Taking another approach, a photolabile 
bPTH-(1-84)-type, if it could be made, might label a different receptor 
subunit. The other bands evident on the radioautograph represent some form 
of non-specific binding since they are not affected by competition, but 
what is especially interesting is the constancy of the pattern. They may 
prove to be membrane proteins in close approximation to the PTH receptor. 
The much enhanced potency of (1)-FNPA125I-PTH was a serendipitous 
discovery. Modification of the lysine (-amino groups is apparently a fer¬ 
tile area for the design of super-potent PTH agonists. The group Fluoro- 
2-Nitrobenzene, FNPA without the azide moiety, would be a good first 
choice to follow this up. 
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The entire receptor complex for parathyroid hormone will undoubtedly 
turn out to be very complicated. This work is just a beginning in studies 
on the receptor proper and as with most beginnings it raises many questions 
The development of photolabile ^^I-labelled PTH analogues is an important 
step. Aside from the question of whether they have identified receptor or 
receptor subunit, their biological activity in vitro and their specifi¬ 
city for certain membrane proteins in dog renal membranes have been demon¬ 
strated. Of immediate use is their role as probes in other tissues where 
their labelling of similar protein(s) or entirely different protein(s) 
would have important implications. As for answering the question of 
receptor vs. receptor subunit, purification and study of the 70,000 






CM Pl, S 0) 
i—i .-O ^d c —4 CO O ' * H 00 o on CN o O CN 
cd *——. i 
CT3 CO CN UO *-H o CN On! o t—H r—H co 
I CO <f 
O 1-1 CO JP 






P-4 ’r-l TJ 
-O 6 (1) 
,—, cd c r—H 00 r—1 CN r-H 00 oo ON CN o o CN o 
<t 1 • r—1 
CO cd co CN I/O i—i o CM t-H O r-H r-H CO CO 
1-4 <t -u 
Pm CO 42 









*> H -H T3 
CM CL, g QJ 
f—4 ^ Cd 3 
cd '—• i -r-t 
Ext ^ co 
I CO vf 4J 
Q 14 co Cl 





P-4 -r-l TC 
-Q B QJ 
■-' Bl C 
<t I 
co /-s cd 
1-4 <f 4-1 
>iCd ,D 








co co uo O CO CM —4 <t CO CO CM 
OP.—l<j-CMONOOON<tONr^CMO^H 
cOCOlO^mOCOCMO'C'OOCOCOCM 
CM 00 CO t-H 00 ON ON ON CN ON 00 CN o 
CO CN UO t-H O CN -H o <1* o o CO co 
co co COCM^H<)-r-4t-HCOCOCM 
c "d a i-i 3 Po cd t-H -U ai 3 1-1 a) CO CO 00 
• rH CO <u r-H t-H t—H cd ai t-H 0) Pm J3 kO • rH 1-4 
































































































































































Table II: Biological activity of Bovine Parathyroid Hormone 










none l-34c 5400 (3900-8000) 100 
[Tyr34] 1-34 amidec 16000 (11000-23000) 300 
[D-Tyr34] 1-34 amide 14500 (11000-17000) 270 
[D-Tyr34] 2-34 amide 130d(120-150) 3 
[D-Val2 
D-Tyr34] 
2-34 amide 90d(60-100) 2 
[D-Val2 
D-Tyr34] 
1-34 amide 80d(60-100) 1 
aCombined potency estimate based on three independent assays except 
for the compound [D-Tyr34]bPTH-(l-34)-amide. Limits in parenthesis 
represent standard error of the mean for each of the peptides, except 
for [D-Tyr34]bPTH-(l-34)-amide, for which 95% confidence limits are 
provided. Peptides were assayed without prior treatment with reducing 
agents. ^Relative potency calculated on the basis of the mean potency 
with the activity of the reference peptide, unsubstituted bPTH(l-34), 
taken as 100%. cPotencies previously reported (Potts et al., 1971; 
Rosenblatt & Potts, 1977). ^Response curve nonparallel to that of the 
standard. Although the potency value cannot be formally assigned, 
potency has been estimated by comparing the activity with that of the 
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HUMAN -Q BOVINE-(3 PORCINE - 
Figure 1. The 84 amino acid sequence of human 
parathyroid hormone (hPTH) and the variations 





Figure 2. The full sequence of bovine 
parathyroid hormone, bPTH-(l-84). 
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Figure 3. Sequence of the four D-amino acid-containing 
analogues. All four contain the carboxyamide function and 
the D-tyrosine substitution for phenylalanine. In two of the 
analogues, D-valine was substituted for the L-valine at 
position 2. Additionally, two of the analogues had position 
1 deleted. The four analogues are [D-Tyr34lbPTH-(l-34)-amide, 










Figure 4. Schematic of Merrifield solid-support synthesis 
of a two-amino acid peptide. The deprotect and couple steps 
are repeated as many times as needed to elongate the peptide. 
-42- 

Peptide Sequence Content % 
Major Peptide A B C - D - E - F - G 
Error Peptides 
- deletion of C A B D - E - F - G - H 
- deletion of E A B C - D - F - G - H 
- deletion of G A B C - D - E _ f - H 
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 
Edmaji Yields . 1n„ 
o* A 100 
/o 
B 100 C 95 D 95 E 90 F 90 G 85 
D 5 E 5 F 10 G 10 H IS 
Figure 5. Edman degradation performed on a peptide ABCD...which is 
contaminated by small amounts of deletion error-containing peptides 
results in a "preview" of the next amino acid. At the point of the 
deletion, the "preview" amino acid occurs in an amount corresponding 
to the number of deletion containing peptides. As the sequencing 
proceeds, the effect of successive deletions is cumulative resulting 
in an amplification of even a very small error. 
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0 5 10 15 
TIME (min) 
Figure 6. Reverse-phase high-pressure 
liquid chromatographic profile of 
[D-Val^ D-Tyr-^]bPTH-( l-34)-amide , one 
of the four D-amino acid containing analo¬ 
gues derived from a single synthesis. 
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Figure 7. Composite of representative rat renal cortical 
adenylate cyclase assays of the following: [D-Tyr34]bPTH- 
(l-34)-amide (■); native bovine hormone standard, bPTH-(l-84), 
2500 MRC units/mg (•); [D-Tyr34]bPTH-(2-34)-amide 0*); 
[D-Val2, D-Tyr34]bPTH-(2-34)-amide (o); [D-Val2, D-Tyr34] 
bPTH-(1-34)-amide O); [D-Tyr34]bPTH-(l-34)-amide (x), 
assayed 18 weeks after purification was completed. Each 
point is the mean of triplicate determinations. Peptide 
concentration was quantitated by amino acid analysis. Each 
peptide was assayed within 4 weeks of completion of 




Figure 8. Biological activity of [D-Tyr]bPTH- 
(l-34)-amide vs. time elapsed from completion of 
synthesis. Bioactivity was determined without 
prior treatment with reducing agents. Error bars 
depict standard error of the mean. 
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Figure 9. Sequence of the three D-amino acid-containing sulfur- 
free analogues. All three contain the carboxyamide function and 
the D-tyrosine substitution for phenylalanine. In two of the 
analogues, D-valine was substituted for the L-valine at position 
2. Additionally, in one of the analogues position 1 was deleted 
(arrow). The three analogues are [Nle8, Nle18, D-Tyr34]bPTH- 
(l-34)-amide, [D-Val2, Nle8, Nle18, D-Tyr34]bPTH-(l-34)-amide, 
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Figure 10. Reverse-phase high-pressure liquid chroma¬ 
tographic profile of [Nle®, Nle^, D-Tyr]bPTH-( 1-34) 
amide, one of the three D-amino acid-containing sulfur 




Figure 11. Composite of representative rat renal 
cortical adenylate cyclase assays of the following: 
[Nle8, Nle18, D-Tyr34 ]bPTH-( l-34)-amide (a); native 
bovine hormone standard, bPTH-(l-84), 2500 MRC 
units/mg (a); [D-Val2, Nle8, Nle18, D-Tyr34]bPTH- 
(1-34)-amide (□); [D-Val2, Nle8, Nle18, D-Tyr34] 
bPTH-(2-34)-amide (*) . Each point is the mean of 
triplicate determinations. Peptide concentration 
was quantitated by amino acid analysis. 
-49- 

Figure 12. Binding properties of four analogues of PTH in a canine 
renal radioreceptor assay for PTH. ^^I-[Nle®, Nle^, Tyr~^]bPTH- 
(l-34)-amide was used as the radioligand. Inhibition of the radioligand 
specific-binding is shown by (•) for [Nle®, Nle^} Tyr^]bPTH-( 1-34)- 
amide, by (A) for [Nle^, Nle^, D-Tyr^ ]bPTH-( l-34)-amide, by O) 
for [D-Val^, Nle®, Nle-*- , D-Tyr^]bPTH-( 1-34)-amide and by (o) for 
[D-Val^, Nle^, Nle^, D-Tyr^]bPTH-( 2-34)-amide . Each point is the mean of 




SITE INHIBITORY REGION 
Figure 13. The full sequence of bPTH-(l-84). 
The fully biologically active region 1 to 34 
is enclosed in brackets. This region is 
further resolvable into 1) an amino-terminus 
region (positions 1 and 2) that is essential 
for biological activity once binding to the 
receptor has occurred and 2) a region (posi¬ 
tions 3 to 34) that binds the PTH receptor 




















Figure 14, Elution profile of iodinated peptide after 
purification on a Bio-Gel P-2 column in 0.1 M HOAc. Peak 
I, labelled peptide; Peak II, chloramine-T; Peak III, 
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Figure 15. Primary structure of the photolabile PTH 
analogues. The analogues are sulfur-free versions to 
withstand the oxidative conditions needed to attach 
12^1 to the terminal tyrosine. Solid arrows 
point to the three lysine residues that the aryl 
azides may react with. The discontinuous arrow points 
to the amino group on alanine (see text). Also de¬ 
picted are the two aryl azides used: FNPA, 4-Fluoro- 
3-Nitrophenyl azide and SMHA, N-Succinimidyl-6- 




Figure 16. Composite HPLC of top, (1)-FNPA-^27I- 
[Nle8, Nlel8, Tyr34]bPTH-(l-34)-amide; center, 
1271-[Nle8, Nle ^ 8 Tyr34lbPTH-(1-34)-amide; 
bottom [Nle8, Nle^8, Tyr-^4]bPTH-( l-34)-amide . 
Buffers (as described in the text) were the same for 
all three, running on a linear 30 min (0-100% Buffer 
2) gradient. For FNPA-bPTH, top, this analytical 
run shows little heterogeneity. Further, the two 
peaks corresponding to the unreacted ligands which 
would give an erroneous cyclase assay elute at dif¬ 
ferent points and are not contaminants in the HPLC 




Lane 1 Lane 2 
Figure 17. Radioautograph of 9 - 20% SDS-Polyacrylamide 
gradient gel. Both lanes contain membrane and SMHA-125j 
[Nle®, Nle^S, Tyr^]bPTH-(1-34)-amide incubated and 
exposed to light as explained in the text. In addition. 
Lane 2 contains 10 ug of unlabelled [Nle^, Nle^, Tyr^j 
bPTH-(l-34)-amide for competition. One band, correspon¬ 
ding to a molecular weight of 70,000 - 1000 daltons, 




























10,000 —f i i i i i i i i i 
0.! 0.2 0.3 0.4 0.5 06 0.7 0.8 0.9 1.0 
d/L 
Figure 18. Straight-line functions based on d/L vs. log molecular 
weights of known proteins. The difference in plot slopes is due to the 
two separate gels represented. Gel 1 (•) was loaded with FNPA-labelled 
membranes and Gel 2 (•) was loaded with SMHA-labelled membranes. Both 
gels were 9 - 20% SDS-polyacrylamide gradients. The disappearance of 
the receptor/receptor subunit band corresponded to the same weight, 
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